Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;53(11):1169-1173.
doi: 10.1055/a-1324-8498. Epub 2021 Jan 21.

Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice

Affiliations

Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice

Gontrand Lopez Nava et al. Endoscopy. 2021 Nov.

Abstract

Background: The POSE-2 procedure shortens and narrows the stomach using multiple full-thickness plications in the gastric body. We studied the efficacy and safety of POSE-2 for obesity at 1 year in a real-world setting.

Methods: We reviewed the records of 75 patients who underwent POSE-2 at our unit. The primary outcome was percentage total body weight loss (%TBWL) at 1 year. Secondary outcomes were safety and durability. We used linear mixed model analysis.

Results: 46 patients completed 1 year. Mean age and body mass index (BMI) were 49.3 years (standard deviation [SD] 10.2) and 38.2 kg/m2 (SD 6.6), respectively. Technical success rate was 98.7 % (n = 74). Mean TBWL, %TBWL, and BMI decline at 1 year were 20 kg (SD 12.7), 17.8 % (SD 9.5), 7 kg/m2 (SD 4.3). Adverse events occurred in four patients. The median length of stay was 1 day. Endoscopy at 1 year in 15 patients showed intact sutures and a reduction in gastric length compared with baseline (26.9 cm [SD 5.3] vs. 35.7 cm [SD 3.5]; P < 0.001).

Conclusion: POSE-2 induced significant weight loss at 1 year. It appears to be safe, durable, and required only a short hospital stay.

PubMed Disclaimer

Conflict of interest statement

Gontrand Lopez Nava is a paid consultant for Apollo Endosurgery, USGI Medical, USA and Nitinotes. All other authors declare that they have no conflicts of interest.

Comment in

LinkOut - more resources